Drug intelligence / Profile preview

TTI-102

Development stage: Discontinued
Lead developer: Tvardi Therapeutics
Modality: Small Molecules

Overview

TTI-102 is a small molecule drug that acts as a **STAT3 inhibitor**. It was initially developed by Tvardi Therapeutics for the treatment of various cancers and conditions involving aberrant STAT3 activation. The drug's mechanism involves inhibiting the activity of signal transducer and activator of transcription 3 (**STAT3**), a transcription factor implicated in cancer pathogenesis and other diseases. TTI-102's development was discontinued before reaching approval[9][7]. There are no current indications or active clinical development programs reported for TTI-102 as of the latest available information.

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)

Beyond the preview

Go deeper on TTI-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TTI-102.